81% rise in Victoza sales drives Novo Nordisk earnings

Article Date: 27/04/2012 10:33
81% rise in Victoza sales drives Novo Nordisk earnings

Vacancy Search

Quick job search

Advanced Search

Latest News

AZ, Immunocore to test melanoma immunotherapy combos

AZ, Immunocore to test melanoma immunotherapy combos

FDA OKs first generic of Teva's MS drug Copaxone

FDA OKs first generic of Teva's MS drug Copaxone

Sanofi and Innate partner for targeted antibodies

Sanofi and Innate partner for targeted antibodies

Actelion moves MS pill into PhIII

Actelion moves MS pill into PhIII

Priority review for AbbVie's hep C drug in Japan

Priority review for AbbVie's hep C drug in Japan

FDA OKs first new chronic heart failure drug in a decade

FDA OKs first new chronic heart failure drug in a decade

Pfizer calls time early on Ibrance study

Pfizer calls time early on Ibrance study

US Orphan status for AZ' mesothelioma drug

US Orphan status for AZ' mesothelioma drug

Galapagos moves towards RA deal but a dark horse remains on the horizon

Galapagos’s oral rheumatoid arthritis drug GLPG0634 has cleared the first obstacle in the path to a full-blown licensing deal with AbbVie, hitting the primary endpoint of a crucial phase IIb...

Biocartis flies the flag with unusual Brussels medtech listing

So far this year there has only been one European medtech IPO, and that was the first for eight months. And since the start of 2014 all Eurozone IPOs have been in Paris (see table). So why...
more news